KDDH saves lives, cost with diabetes treatment
visalia – At 13.2%, nowhere in California is the prevalence of diabetes higher than Tulare County and no hospital knows the challenge of diabetes more than Kaweah Delta Medical Center. With 30 to 40 percent of all hospitalized patients requiring insulin therapy, not just those with diabetes, the common problem of insulin mismanagement has significant impact on care quality, patient safety and patient experience, as well as cost and value. As the county’s largest public hospital, Kaweah Delta has to find innovative strategies to standardize diabetes care and prioritize glycemic management for all patients requiring insulin therapy with little endocrinology support and significant variation in provider practice.
In March 2016, Glytec implemented a cast study at the Visalia-based regional academic hospital to track the effectiveness of its eGlycemic Management System, or eGMS. Glytec’s diabetes therapy management software enables healthcare organizations to standardize acute and chronic care, and achieve best practice for glucose control. eGMS centers on an FDA-cleared insulin dosing solution that supports personalized intravenous and subcutaneous therapy for adults and children. It integrates seamlessly with EMR and connected device systems for streamlined use across the entire continuum of care, including at-home, provider-directed care managed through telehealth, population health and other value-based programs.
The study examined pre-eGMS baseline data from calendar year 2015 to post-eGMS data from March 2016 to March 2017. Rose Newsom, Director of Nursing Practice, described how Kaweah Delta Medical Center’s transition to an insulin regimen using eGMS, was a driving force behind dramatic improvements in both clinical and financial outcomes at the 6th International Hospital Diabetes Meeting May 19-20 in Atlanta, Ga.
The case study reported that eGMS enabled Kaweah Delta to adopt the most effective and efficient insulin therapy, resulting in first-year cost savings of $7,489,420. The savings were primarily rooted in two key areas: 73.7% reduction in severe hypoglycemia; and a 47.4% reduction in point-of-care blood glucose testing. The study also showed a 23.1% reduction in overall length of stay for patients who received insulin therapy.
“Hospital executives have a lot to contend with as they prepare their organizations for more value-based reimbursement. These presentations and studies again demonstrate why glycemic management truly merits prioritization when it comes to improving quality of care, patient safety, cost and value,” says Raymie McFarland, Glytec’s VP of Quality Initiatives. “There’s an abundance of compelling evidence surrounding the need for standardization and the value of adopting best practice. The case study presented by Rose Newsom of Kaweah Delta Medical Center is a great example of how employing a computerized, evidence-based systems approach with Glytec’s eGMS can result in an annualized cost savings of nearly $7.5 million for a single institution.”
Kaweah Delta was among a series of studies and presentations at the hospital conference that highlighted the high cost of poor glucose management, and in particular, severe hypoglycemia in the acute care setting. And Kaweah Delta wasn’t the only Valley success story.
Dr. Greg Maynard, Chief Quality Officer and Clinical Professor of Medicine at UC Davis Medical Center in Sacramento, California, long recognized as a leading voice in the effort to improve inpatient glucose management, preceded Newsom with a presentation focusing on the need to reduce hypoglycemia, which he emphasized as being “too common and costly” as well as “preventable.” Maynard suggested that perhaps it’s time the medical community classify severe hypoglycemia as a ‘never event,’ offering an impressive array of compelling data to support this assertion, including the fact 57% of adverse drug events involve hypoglycemic agents.